Literature DB >> 24183837

Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Dana C Miskulin1, Kaleab Z Abebe2, Arlene B Chapman3, Ronald D Perrone4, Theodore I Steinman5, Vicente E Torres6, K Ty Bae2, William Braun7, Franz T Winklhofer8, Marie C Hogan6, Fred Rahbari-Oskoui3, Charity G Moore2, Michael F Flessner9, Robert W Schrier10.   

Abstract

BACKGROUND: In people with early autosomal dominant polycystic kidney disease (ADPKD), average total kidney volume (TKV) is 3 times normal and increases by an average of 5% per year despite a seemingly normal glomerular filtration rate (GFR). We hypothesized that increased TKV would be a source of morbidity and diminished quality of life that would be worse in patients with more advanced disease. STUDY
DESIGN: Cross-sectional. SETTING & PARTICIPANTS: 1,043 patients with ADPKD, hypertension, and a baseline estimated GFR (eGFR)> 20mL/min/1.73m(2). PREDICTORS: (1) eGFR, (2) height-adjusted TKV (htTKV) in patients with eGFR> 60mL/min/1.73m(2). OUTCOMES: 36-Item Short Form Health Survey (SF-36) and the Wisconsin Brief Pain Survey. MEASUREMENTS: Questionnaires were self-administered. GFR was estimated from serum creatinine using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. htTKV was measured by magnetic resonance imaging.
RESULTS: Back pain was reported by 50% of patients, and 20% experienced it "often, usually, or always." In patients with early disease (eGFR> 60mL/min/1.73m(2)), there was no association between pain and htTKV, except in patients with large kidneys (htTKV> 1,000mL/m). Comparing across eGFR levels and including patients with eGFRs< 60mL/min/1.73m(2), patients with eGFRs of 20-44mL/min/1.73m(2) were significantly more likely to report that pain impacted on their daily lives and had lower SF-36 scores than patients with eGFRs of 45-60 and ≥60mL/min/1.73m(2). Symptoms relating to abdominal fullness were reported by 20% of patients and were related significantly to lower eGFRs in women, but not men. LIMITATIONS: TKV and liver volume were not measured in patients with eGFR < 60mL/min/1.73m(2). The number of patients with eGFRs< 30mL/min/1.73m(2) is small. Causal inferences are limited by cross-sectional design.
CONCLUSIONS: Pain is a common early symptom in the course of ADPKD, although it is not related to kidney size in early disease (eGFR> 60mL/min/1.73m(2)), except in individuals with large kidneys (htTKV> 1,000 mL/m). Symptoms relating to abdominal fullness and pain are greater in patients with more advanced (eGFR, 20-45mL/min/1.73m(2)) disease and may be due to organ enlargement, especially in women. More research about the role of TKV in quality of life and outcomes of patients with ADPKD is warranted.
Copyright © 2014 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease (ADPKD); activities of daily life; chronic kidney disease (CKD); extrarenal symptoms; patient-reported outcomes; quality of life (QoL); renal disease

Mesh:

Year:  2013        PMID: 24183837      PMCID: PMC4075014          DOI: 10.1053/j.ajkd.2013.08.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  23 in total

1.  Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.

Authors:  Thomas Schnelldorfer; Vicente E Torres; Shaheen Zakaria; Charles B Rosen; David M Nagorney
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease.

Authors:  Bernard F King; Judd E Reed; Erik J Bergstralh; Patrick F Sheedy; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2000-08       Impact factor: 10.121

Review 4.  Autosomal dominant polycystic kidney disease.

Authors:  P A Gabow
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

Review 5.  Pain management in polycystic kidney disease.

Authors:  Z H Bajwa; S Gupta; C A Warfield; T I Steinman
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

6.  Sex differences and personality factors in responsivity to pain.

Authors:  M W Otto; M J Dougher
Journal:  Percept Mot Skills       Date:  1985-10

7.  Pain patterns in patients with polycystic kidney disease.

Authors:  Zahid H Bajwa; Khuram A Sial; Atif B Malik; Theodore I Steinman
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

8.  "An evil heritage": interview study of pain and autosomal dominant polycystic kidney disease.

Authors:  Susanne Heiwe; Monica Bjuke
Journal:  Pain Manag Nurs       Date:  2009-09       Impact factor: 1.929

9.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

Review 10.  Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

Authors:  Jared J Grantham; Arlene B Chapman; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2005-10-19       Impact factor: 8.237

View more
  40 in total

Review 1.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

2.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

3.  Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Koki Mise; Toshiharu Ueno; Keiichi Sumida; Masayuki Yamanouchi; Noriko Hayami; Junichi Hoshino; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi
Journal:  J Am Soc Nephrol       Date:  2015-11-30       Impact factor: 10.121

Review 4.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

5.  Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.

Authors:  Myrte K Neijenhuis; Tom J G Gevers; Marie C Hogan; Patrick S Kamath; Titus F M Wijnands; Ralf C P M van den Ouweland; Marie E Edwards; Jeff A Sloan; Wietske Kievit; Joost P H Drenth
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

Review 6.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Authors:  Niek F Casteleijn; Folkert W Visser; Joost P H Drenth; Tom J G Gevers; Gerbrand J Groen; Marie C Hogan; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

Review 7.  Patient-Reported Outcomes in Glomerular Disease.

Authors:  David T Selewski; Aliza Thompson; Sarrit Kovacs; Elektra J Papadopoulos; Noelle E Carlozzi; Howard Trachtman; Jonathan P Troost; Peter A Merkel; Debbie S Gipson
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-03       Impact factor: 8.237

Review 8.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

9.  Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015.

Authors:  Cynthia Willey; Siddhesh Kamat; Robert Stellhorn; Jaime Blais
Journal:  Kidney Dis (Basel)       Date:  2019-01-09

Review 10.  Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.